Core Points - SciSparc Ltd. has been granted an additional 180-day compliance period by Nasdaq to regain compliance with the minimum bid price rule, extending the deadline to July 14, 2025 [1][3] - The company did not meet the minimum $1.00 bid price requirement during the initial compliance period and has expressed its intention to cure the deficiency, potentially through a reverse share split [2][3] - If the closing bid price reaches at least $1.00 for a minimum of 10 consecutive business days before the deadline, the company will regain compliance [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases [5] - The company is engaged in drug development programs including SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus, utilizing cannabinoid pharmaceuticals [5] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [5]
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement